CRL · 8-K · 20260924PR000142

Strategic Initiatives

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-09-24 · Importance 59 · Surprise 50

Charles River’s Pathway to Purpose strategy includes its Create the Future program, which is expected to generate over $300 million in cumulative savings from 2027 through 2030 through process simplification, automation, and digital enablement. The company plans organic and inorganic investment in bioanalysis, in vitro testing, and related scientific solutions, and targets bioanalysis revenue of approximately $450 million in 2030, representing high-single-digit organic CAGR. It is expanding its Apollo cloud-based platform, which serves more than 18,000 client users, to support Manufacturing Solutions clients. The initiatives are intended to reinforce the company’s position in early-stage drug development and regulated testing.

Key facts

• Charles River plans to expand its use of AI-assisted digital tools to improve operating efficiency, reduce drug development timelines, and enhance client satisfaction. source
• Charles River intends to reinforce its leadership position in early-stage drug development with comprehensive regulated testing capabilities across the R&D continuum through its initiatives and disciplined capital deployment. source